• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Health Canada: Additional Lot of Product Desire Found to Contain an Unlabelled Ingredient

Posted on: Thursday, 5 June 2008, 18:00 CDT

Following a communication issued to Canadians on May 22, 2008, Health Canada is advising consumers that an additional lot of the product Desire has been found to contain an unlabelled prescription drug. This unauthorized product is promoted to enhance male sexual performance and may pose serious health risks in certain patients.

Lab results indicate that lot 84881, in addition to lot 0070263, of the product Desire contains Phentolamine, which should only be used under the supervision of a health care professional. Lot numbers can be found on the back panel. Phentolamine is currently authorized for intravenous use in the prevention and control of high blood pressure in patients with adrenal tumours, and should only be used under the supervision of a health care professional. Patients with pre-existing medical conditions, including those with heart problems, those taking heart or blood pressure medications, or those at risk for strokes, may be at an increased risk of serious health effects.

Use of phentolamine by patients with heart disease can potentially result in serious cardiac side-effects such as low blood pressure, chest pain and abnormal heartbeat. Other side-effects may include dizziness, loss of consciousness, prolonged erection, headache, flushing, nasal congestion, indigestion and abdominal pain.

Desire is labelled as manufactured by Desire LLC, and distributed by StarChem Labs, of Farmingdale, New York. The product may be available at retail outlets across Canada, and over the Internet.

Consumers are advised not to use the product Desire and retailers are advised to remove both lots of the product from their shelves.

For more information, please refer to the warning issued by Health Canada on May 22, 2008 (www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2008/2008_80_e.html).

Consumers requiring more information about this warning can contact Health Canada's public enquiries line at 613-957-2991, or toll free at 1-866-225-0709.

Egalement disponible en francais

 Contacts: Media Inquiries: Health Canada 613-957-2983  Public Inquiries: 613-957-2991 1-866-225-0709  

SOURCE: Health Canada

Source: MARKET WIRE

More News in this Category